TTK Healthcare Ltd
- Market Cap ₹ 1,455 Cr.
- Current Price ₹ 1,030
- High / Low ₹ 1,443 / 991
- Stock P/E 20.6
- Book Value ₹ 768
- Dividend Yield 0.97 %
- ROCE 9.26 %
- ROE 6.89 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 42.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- The company has delivered a poor sales growth of 4.42% over past five years.
- Earnings include an other income of Rs.67.6 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Diversified Diversified Diversified Diversified
Part of BSE SmallCap BSE Allcap BSE Industrials
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 753 | 801 | 825 | |
| 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 767 | 797 | |
| Operating Profit | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 37 | 35 | 28 |
| OPM % | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% | 4% | 3% |
| 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 63 | 85 | 68 | |
| Interest | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 3 |
| Depreciation | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 8 | 9 |
| Profit before tax | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 84 | 108 | 83 |
| Tax % | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | 25% | 25% | |
| 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 63 | 82 | 66 | |
| EPS in Rs | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 44.47 | 57.79 | 46.90 |
| Dividend Payout % | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% | 22% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 4% |
| 3 Years: | 10% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 42% |
| 3 Years: | 22% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 1% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 26% |
| 3 Years: | 29% |
| Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 987 | 1,051 | 1,071 |
| 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 23 | 24 | 27 | |
| 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 183 | 192 | 184 | |
| Total Liabilities | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
| 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 75 | 81 | 78 | |
| CWIP | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 13 | 11 | 12 |
| 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,118 | 1,189 | 1,205 | |
| Total Assets | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 39 | 37 | 18 | 25 | 17 | 20 | 96 | 45 | -25 | -5 | -4 | |
| -15 | -49 | -27 | 5 | -22 | 10 | -13 | -77 | -30 | 32 | 28 | 20 | |
| 2 | 3 | -11 | -23 | -7 | -31 | -10 | -17 | -10 | -12 | -22 | -18 | |
| Net Cash Flow | 0 | -7 | -0 | 0 | -4 | -4 | -4 | 2 | 5 | -6 | 2 | -2 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 | 41 |
| Inventory Days | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 | 107 |
| Days Payable | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 | 106 |
| Cash Conversion Cycle | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 19 | 36 | 43 |
| Working Capital Days | -24 | -31 | -38 | -24 | -30 | -6 | -3 | -32 | -28 | 4 | 49 | 48 |
| ROCE % | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% | 9% | 9% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
1d - Postal ballot seeking shareholder approval to appoint V Sundaresan as Independent Director for five years from Dec 22, 2025.
-
Outcome Of Board Meeting Held On December 22, 2025
22 Dec - Appointed V Sundaresan as Additional Independent Director from 22-Dec-2025 for five years; postal ballot e-voting 26-Dec-2025 to 24-Jan-2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
22 Dec - Appointed V Sundaresan as Additional Independent Director from Dec 22, 2025 for five-year term, subject to postal ballot.
-
Board Meeting Outcome for Board Meeting Outcome Held On December 22, 2025
22 Dec - Appointed V Sundaresan as Additional Independent Director from 22-Dec-2025 for five years; postal ballot voting 26-Dec-2025 to 24-Jan-2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Nov
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Sep 2016TranscriptAI SummaryPPT
Business Segments FY24
1. Consumer Products (~31% revenue, 29% Op. profit): The company markets and distributes products that transcend categories; baby care (Woodward’s Gripe Water), personal care (Eva Deodrants), home care- room & air fresheners (Good Home ), and sexual wellness (Skore).. [1] The Woodward's Gripe Water is one of the oldest FMCG brands worldwide and is a market leader in the Indian colic market. It has been marketed in India since 1928. It has a distribution network of 27 warehouses, 2,600+ distributors, 650+ frontline sales teams, and a reach of ~4 lakh outlets across India. [2]